More Publications by © Chronicle Companies

n+p.PNG
Advertise with Derm.city
Chronicle Companies
Terms of Use Policy
Order "To Heal the Skin"

© Chronicle Companies 2018

Powered by Skin Chronicle International

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle
  • Home

  • Skin Chronicle

  • Primers for your Patient

  • Skin Spectrum Summit

  • Chronicle

  • Contact

  • More...

    News

    More effective rituximab dosing for pemphigus identified

    November 15, 2019

    |

    By John Evans

    Pemphigus vulgaris, H&E stain. Photo by: Nephron via Wikimedia Commons

     

    Prescribing a ‘lymphoma dose’ of the biologic rituximab for pemphigus vulgaris results
    in patients having a much higher chance of achieving complete clearance than a
    ‘rheumatoid arthritis dose,’ according to new findings.


    Published online in JAMA Dermatology (Oct. 23, 2019), the findings come from a cohort
    study of 112 patients with pemphigus. The investigators found that pemphigus patients
    receiving more frequent infusions of the biologic, adjusted for their bodies, were nearly
    three times as likely to achieve complete remission than patients treated with two fixed-
    dose infusions.


    In a press release from the Perelman School of Medicine at the University of
    Pennsylvania in Philadelphia, where the research was conducted, the authors note that
    the U.S. FDA has approved a dosing regimen of rituximab for pemphigus that
    resembles the dosing used to treat rheumatoid arthritis (RA)—a fixed dose of two 1,000
    mg infusions, two weeks apart. In contrast, rituximab dosing for lymphoma is calculated
    by patient height and weight, and infusions are given weekly for four weeks.


    Because many patients’ insurance only covers the lower dose, and there are concerns
    about infection risk with higher doses of immunosuppressants, many doctors favour the
    lower dose for pemphigus.


    “All these reasons made it logical for physicians to use the medication more
    conservatively,” said the study’s senior author Dr. Aimee Payne, director of the Penn
    Clinical Autoimmunity Center of Excellence. “However, our findings suggest that the
    more aggressive lymphoma approach gives a patient the best chance for complete
    remission off oral immune suppressants, and that’s obviously the desired outcome.”


    Controlling for age, sex, pemphigus subtype, BMI, and disease duration, patients in the
    cohort who received lymphoma vs. rheumatoid arthritis dosing were 2.70-fold more
    likely to achieve complete remission that persisted without continuing therapy (called complete remission off therapy or CROT in the paper).


    As well, Dr. Payne and her team found that the odds of achieving complete remission in
    patients over age 65 was almost 10-fold greater than those under age 45, and patients

    with moderate to severe obesity had over 7-fold lower odds of achieving complete
    remission compared to non- or mildly obese patients.


    Regardless of dosing, the authors say in the release that the evidence supports the use
    of rituximab in general for treating pemphigus. Before the medication, the only FDA-
    approved treatment option was a course of steroids. Looking at rituximab’s success in
    both dosing regimens combined, the study showed 48% of patients achieved complete
    remission after just one cycle of the therapy. With repeated cycles, complete remission
    jumped to 71%.


    Serious infections were seen in 5% of patients in this study over the courses of their
    rituximab treatments. That is lower than historical serious infection rates among patients
    treated with high-dose steroid regimens.


    “Rituximab is not a perfect medication since it does weaken one’s immune system like
    steroids do, but it is more effective than steroids in treating this very serious
    autoimmune disease,” said Dr. Payne.


    “This is the first study to provide evidence for physicians to justify a lymphoma-dose
    regimen of rituximab when treating their patients with pemphigus.”

    Tags:

    pemphigus

    pemphigus vulgaris

    rituximab

    biologic therapies

    Perelman School of Medicine

    Aimee Payne

    Please reload

    Featured Posts

    High-dose brachytherapy for BCC, SCC in older patients

    December 6, 2019

    Study: Makeup Products May Harbor Dangerous Bacteria

    December 4, 2019

    Newborn's immune system detects harmful skin bacteria

    December 2, 2019

    Topical rapamycin may slow skin aging

    November 29, 2019

    Statin medications may leave patients vulnerable to skin infections

    November 27, 2019

    Genes show how much sun exposure could lead to melanoma

    November 25, 2019

    Atopic eczema increases fracture risk

    November 22, 2019

    Identifying hyperhotspots in genome could be key in preventative skin cancer treatment

    November 20, 2019

    New guidelines for opioid prescribing practices for dermatologists

    November 18, 2019

    More effective rituximab dosing for pemphigus identified

    November 15, 2019

    Please reload

    Archive

    December 2019 (3)

    November 2019 (11)

    October 2019 (11)

    September 2019 (13)

    August 2019 (13)

    July 2019 (12)

    June 2019 (11)

    May 2019 (17)

    April 2019 (15)

    March 2019 (13)

    February 2019 (11)

    January 2019 (13)

    December 2018 (12)

    November 2018 (13)

    October 2018 (14)

    September 2018 (9)

    August 2018 (9)

    July 2018 (9)

    June 2018 (13)

    May 2018 (11)

    April 2018 (13)

    March 2018 (13)

    February 2018 (14)

    January 2018 (12)

    December 2017 (6)

    November 2017 (11)

    October 2017 (5)

    September 2017 (4)

    August 2017 (6)

    July 2017 (10)

    June 2017 (12)

    May 2017 (17)

    April 2017 (12)

    March 2017 (19)

    February 2017 (11)

    January 2017 (13)

    December 2016 (11)

    November 2016 (13)

    October 2016 (16)

    September 2016 (16)

    August 2016 (14)

    July 2016 (16)

    June 2016 (16)

    May 2016 (22)

    April 2016 (17)

    March 2016 (15)

    February 2016 (12)

    January 2016 (11)

    December 2015 (13)

    November 2015 (19)

    October 2015 (13)

    September 2015 (15)

    July 2015 (3)

    June 2015 (22)

    March 2015 (3)

    Please reload

    Follow Us
    • Grey Facebook Icon
    • Grey YouTube Icon
    • Grey Instagram Icon
    • Grey Twitter Icon